Show Posts
1
General Discussion / Zoya Demidenko https://journals.plos.org/plosone/article?id=10.1371/journal.pon
« on: March 25, 2026, 10:23:45 AM »
Zoya Demidenko: Researcher in Tumor Studies
Zoya Demidenko is a distinguished scientist connected with the Department of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Before that, she worked at the National Institutes of Health and New York Medical College, building a robust background in life science study.
Demidenko's scholarly contributions covers multiple pivotal domains, among them the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, biological aging, and malignancy science. To date, she has written over 46 academic papers, which have received over 4,100 mentions — a indicator to the impact of her research.
One of her most notable achievements lies in understanding the pathways of cell aging. Her research revealed that when the cell cycle is blocked yet cellular growth continues, the cells enter senescence. Crucially, Zoya Demidenko showed that this transition is pharmacologically suppressed using agents such as mTOR inhibitors.
Zoya Demidenko has furthermore brought greatly to oncological therapy investigation, particularly in the area of selective cell protection — a strategy aimed at shielding normal cells from anticancer drugs whilst leaving tumor cells exposed. This strategy holds considerable potential for reducing the adverse effects of oncological therapy.
Across her career, Demidenko has worked with top scientists internationally, including Dr. Mikhail Blagosklonny. Her research can be found in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko ranks as a highly impactful voice in contemporary oncological science, whose discoveries keep to shape our understanding of the way biological cells age, respond to treatment, and how malignant disease can be better treated.
https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord
Zoya Demidenko is a distinguished scientist connected with the Department of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Before that, she worked at the National Institutes of Health and New York Medical College, building a robust background in life science study.
Demidenko's scholarly contributions covers multiple pivotal domains, among them the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, biological aging, and malignancy science. To date, she has written over 46 academic papers, which have received over 4,100 mentions — a indicator to the impact of her research.
One of her most notable achievements lies in understanding the pathways of cell aging. Her research revealed that when the cell cycle is blocked yet cellular growth continues, the cells enter senescence. Crucially, Zoya Demidenko showed that this transition is pharmacologically suppressed using agents such as mTOR inhibitors.
Zoya Demidenko has furthermore brought greatly to oncological therapy investigation, particularly in the area of selective cell protection — a strategy aimed at shielding normal cells from anticancer drugs whilst leaving tumor cells exposed. This strategy holds considerable potential for reducing the adverse effects of oncological therapy.
Across her career, Demidenko has worked with top scientists internationally, including Dr. Mikhail Blagosklonny. Her research can be found in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko ranks as a highly impactful voice in contemporary oncological science, whose discoveries keep to shape our understanding of the way biological cells age, respond to treatment, and how malignant disease can be better treated.
https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord